Literature DB >> 12411394

Rac-dependent monocyte chemoattractant protein-1 production is induced by nutrient deprivation.

Neuza H M Lopes1, Sanjay S Vasudevan, David Gregg, Balakrishnan Selvakumar, Patrick J Pagano, Herve Kovacic, Pascal J Goldschmidt-Clermont.   

Abstract

Under ischemic conditions, the vessel wall recruits inflammatory cells. Human aortic endothelial cells (HAECs) exposed to hypoxia followed by reoxygenation produce monocyte chemoattractant protein-1 (MCP-1); however, most experiments have been performed in the presence of nutrient deprivation (ND). We hypothesized that ND rather than hypoxia mediates endothelial MCP-1 production during ischemia, and that the small GTP-binding protein Rac1 and reactive oxygen species (ROS) are involved in this process. ND was generated by shifting HAECs from 10% to 1% FBS. Superoxide production by HAECs was increased 6 to 24 hours after ND, peaking at 18 hours. MCP-1 production was increased over a similar time frame, but peaked later at 24 hours. These effects were blocked by treatment with antioxidants such as superoxide dismutase mimetic and N-acetylcysteine (NAC), or NADPH oxidase inhibitors, DPI and gp91ds-tat. Superoxide and MCP-1 production were enhanced by RacV12 (constitutively active) in the absence of ND, and were inhibited by RacN17 (dominant-negative) adenoviral transduction under ND, suggesting that the small G-protein Rac1 is required. In conclusion, ND, an important component of ischemia, is sufficient to induce MCP-1 production by HAECs, and such production requires a functional Rac1, redox-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411394     DOI: 10.1161/01.res.0000040421.54108.81

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

Review 1.  Application of angiogenesis to clinical dermatology.

Authors:  Levi E Fried; Jack L Arbiser
Journal:  Adv Dermatol       Date:  2008

Review 2.  Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors.

Authors:  M Eugenia Cifuentes-Pagano; Daniel N Meijles; Patrick J Pagano
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 3.  The quest for selective nox inhibitors and therapeutics: challenges, triumphs and pitfalls.

Authors:  Eugenia Cifuentes-Pagano; Daniel N Meijles; Patrick J Pagano
Journal:  Antioxid Redox Signal       Date:  2013-12-14       Impact factor: 8.401

4.  Cdc42 is required for proper growth and development in the fungal pathogen Colletotrichum trifolii.

Authors:  Changbin Chen; Young-Sil Ha; Ji-Young Min; Stephen D Memmott; Martin B Dickman
Journal:  Eukaryot Cell       Date:  2006-01

Review 5.  NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Authors:  Becky A Diebold; Susan M E Smith; Yang Li; J David Lambeth
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

Review 6.  Role of oxidative stress and nitric oxide in atherothrombosis.

Authors:  Edith Lubos; Diane E Handy; Joseph Loscalzo
Journal:  Front Biosci       Date:  2008-05-01

Review 7.  NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS.

Authors:  Eugenia Cifuentes-Pagano; Gabor Csanyi; Patrick J Pagano
Journal:  Cell Mol Life Sci       Date:  2012-05-15       Impact factor: 9.261

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.